Pesquisa | BVS Doenças Infecciosas e Parasitárias

1.

Weekly chemotherapy with cisplatin and paclitaxel in advanced NSClC: a phase II study.

Buccheri, G; Ferrigno, D; Giordano, M C.

Monaldi Arch Chest Dis ; 65(2): 75-81, 2006 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-16913577

2.

A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG)

Buccheri, G; Ferrigno, D.

Eur J Cancer ; 30A(10): 1424-31, 1994.

Artigo em Inglês | MEDLINE | ID: mdl-7833096

3.

Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.

Buccheri, G; Ferrigno, D; Tamburini, M.

Eur J Cancer ; 32A(7): 1135-41, 1996 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-8758243

4.

Haemostatic abnormalities in lung cancer: prognostic implications.

Buccheri, G; Ferrigno, D; Ginardi, C; Zuliani, C.

Eur J Cancer ; 33(1): 50-5, 1997 Jan.

Artigo em Inglês | MEDLINE | ID: mdl-9071899

5.

Detection of suspected primary lung cancer by scintigraphy with indium-111-anti-carcinoembryonic antigen monoclonal antibodies (type F023C5)

Biggi, A; Buccheri, G; Ferrigno, D; Viglietti, A; Farinelli, M C; Comino, A; Leone, A; Quaranta, M; Taviani, M.

J Nucl Med ; 32(11): 2064-8, 1991 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-1941139

6.

Aspects of quality-of-life in patients with lung-cancer - a 3 observer evaluation study.

Buccheri, G; Vola, F; Ferrigno, D.

Int J Oncol ; 2(4): 537-44, 1993 Apr.

Artigo em Inglês | MEDLINE | ID: mdl-21573589

7.

Nuclear medicine imaging in lung cancer.

Buccheri, G; Ferrigno, D; Biggi, A.

Int J Oncol ; 10(4): 847-55, 1997 Apr.

Artigo em Inglês | MEDLINE | ID: mdl-21533455

8.

The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer. Diagnostic yield and comparison with conventional staging methods.

Buccheri, G; Ferrigno, D.

Chest ; 107(2): 471-6, 1995 Feb.

Artigo em Inglês | MEDLINE | ID: mdl-7842779

9.

Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer.

Buccheri, G; Ferrigno, D.

Chest ; 93(3): 565-70, 1988 Mar.

Artigo em Inglês | MEDLINE | ID: mdl-3342667

10.

Prognostic value of the tissue polypeptide antigen in lung cancer.

Buccheri, G; Ferrigno, D.

Chest ; 101(5): 1287-92, 1992 May.

Artigo em Inglês | MEDLINE | ID: mdl-1582286

11.

Prognostic value of stage grouping and TNM descriptors in lung cancer.

Buccheri, G; Ferrigno, D.

Chest ; 117(5): 1247-55, 2000 May.

Artigo em Inglês | MEDLINE | ID: mdl-10807807

12.

Cranial computed tomography as a part of the initial staging procedures for patients with non-small-cell lung cancer.

Ferrigno, D; Buccheri, G.

Chest ; 106(4): 1025-9, 1994 Oct.

Artigo em Inglês | MEDLINE | ID: mdl-7924469

13.

Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.

Buccheri, G; Ferrigno, D.

J Thorac Cardiovasc Surg ; 122(5): 891-9, 2001 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-11689793

14.

Exercise testing in radiologically-limited, simple pulmonary silicosis.

Violante, B; Brusasco, V; Buccheri, G.

Chest ; 90(3): 411-5, 1986 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-3743156

15.

Diagnostic, morphologic, and histopathologic correlates in bronchogenic carcinoma. A review of 1,045 bronchoscopic examinations.

Buccheri, G; Barberis, P; Delfino, M S.

Chest ; 99(4): 809-14, 1991 Apr.

Artigo em Inglês | MEDLINE | ID: mdl-2009779

16.

Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumor activity?

Buccheri, G; Marino, P; Preatoni, A; Ferrigno, D; Moroni, G A.

Chest ; 99(6): 1433-7, 1991 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-2036827

17.

Anti-CEA immunoscintigraphy might be more useful than computed tomography in the preoperative thoracic evaluation of lung cancer. A comparison between planar immunoscintigraphy, single photon emission computed tomography (SPECT), and computed tomography.

Buccheri, G; Biggi, A; Ferrigno, D; Leone, A; Taviani, M; Quaranta, M.

Chest ; 104(3): 734-42, 1993 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-8365283

18.

Serum biomarkers of non-neuron-endocrine origin in small-cell lung cancer: a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase.

Buccheri, G; Ferrigno, D.

Lung Cancer ; 30(1): 37-49, 2000 Oct.

Artigo em Inglês | MEDLINE | ID: mdl-11008008

19.

Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?

Ferrigno, D; Buccheri, G.

Lung Cancer ; 29(2): 91-104, 2000 Aug.

Artigo em Inglês | MEDLINE | ID: mdl-10963840

20.

Monitoring lung cancer with tissue polypeptide antigen: an ancillary, profitable serum test to evaluate treatment response and posttreatment disease status.

Buccheri, G; Ferrigno, D.

Lung Cancer ; 13(2): 155-68, 1995 Oct.

Artigo em Inglês | MEDLINE | ID: mdl-8581395

BVS Doenças Infecciosas e Parasitárias

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

Weekly chemotherapy with cisplatin and paclitaxel in advanced NSClC: a phase II study.

A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG)

Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.

Haemostatic abnormalities in lung cancer: prognostic implications.

Detection of suspected primary lung cancer by scintigraphy with indium-111-anti-carcinoembryonic antigen monoclonal antibodies (type F023C5)

Aspects of quality-of-life in patients with lung-cancer - a 3 observer evaluation study.

Nuclear medicine imaging in lung cancer.

The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer. Diagnostic yield and comparison with conventional staging methods.

Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer.

Prognostic value of the tissue polypeptide antigen in lung cancer.

Prognostic value of stage grouping and TNM descriptors in lung cancer.

Cranial computed tomography as a part of the initial staging procedures for patients with non-small-cell lung cancer.

Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.

Exercise testing in radiologically-limited, simple pulmonary silicosis.

Diagnostic, morphologic, and histopathologic correlates in bronchogenic carcinoma. A review of 1,045 bronchoscopic examinations.

Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumor activity?

Anti-CEA immunoscintigraphy might be more useful than computed tomography in the preoperative thoracic evaluation of lung cancer. A comparison between planar immunoscintigraphy, single photon emission computed tomography (SPECT), and computed tomography.

Serum biomarkers of non-neuron-endocrine origin in small-cell lung cancer: a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase.

Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?

Monitoring lung cancer with tissue polypeptide antigen: an ancillary, profitable serum test to evaluate treatment response and posttreatment disease status.